Statement Of Cash Flows [Abstract]

ERYTECH Pharma S.A. - Filing #880081

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	53 797 EUR	53 797 EUR	—	73 300 EUR	73 300 EUR	62 659 EUR	62 659 EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for income tax expense	—	—	2,000 EUR	—	3,000 EUR	—	—	1,000 EUR	—
Adjustments for decrease (increase) in inventories	—	—	— EUR	—	358,000 EUR	—	—	1 038 EUR	—
Adjustments for depreciation and amortisation expense	—	—	5 377 EUR	—	4 991 EUR	—	—	4 216 EUR	—
Adjustments for provisions	—	—	135,000 EUR	—	57,000 EUR	—	—	192,000 EUR	—
Adjustments for share-based payments	—	—	1 323 EUR	—	1 179 EUR	—	—	1 359 EUR	—
Adjustments for losses (gains) on disposal of non-current assets	—	—	17,000 EUR	—	22,000 EUR	—	—	42,000 EUR	—
Income taxes paid (refund), classified as operating activities	—	—	2,000 EUR	—	— EUR	—	—	— EUR	—
Cash flows from (used in) operating activities	—	—	56 770 EUR	—	51 720 EUR	—	—	43 310 EUR	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	—	— EUR	—	83,000 EUR	—	—	— EUR	—
Purchase of property, plant and equipment, classified as investing activities	—	—	298,000 EUR	—	1 139 EUR	—	—	20 117 EUR	—
Purchase of intangible assets, classified as investing activities	—	—	— EUR	—	2,000 EUR	—	—	16,000 EUR	—
Proceeds from sales of other long-term assets, classified as investing activities	—	—	145,000 EUR	—	4,000 EUR	—	—	414,000 EUR	—
Purchase of other long-term assets, classified as investing activities	—	—	192,000 EUR	—	421,000 EUR	—	—	119,000 EUR	—
Cash flows from (used in) investing activities	—	—	345,000 EUR	—	1 475 EUR	—	—	19 838 EUR	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	—	34 631 EUR	—	118,000 EUR	—	—	— EUR	—
Proceeds from issuing other equity instruments	—	—	— EUR	—	12,000 EUR	—	—	47,000 EUR	—
Proceeds from borrowings, classified as financing activities	—	—	12 157 EUR	—	27 134 EUR	—	—	— EUR	—
Repayments of borrowings, classified as financing activities	—	—	— EUR	—	62,000 EUR	—	—	738,000 EUR	—
Payments of lease liabilities, classified as financing activities	—	—	1 702 EUR	—	1 615 EUR	—	—	978,000 EUR	—
Interest paid, classified as financing activities	—	—	374,000 EUR	—	326,000 EUR	—	—	195,000 EUR	—
Other inflows (outflows) of cash, classified as financing activities	—	—	— EUR	—	— EUR	—	—	38,000 EUR	—
Cash flows from (used in) financing activities	—	—	44 712 EUR	—	25 449 EUR	—	—	40,000 EUR	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	—	1 656 EUR	—	981,000 EUR	—	—	1 910 EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	—	10 747 EUR	—	28 727 EUR	—	—	61 198 EUR	—
Cash and cash equivalents	33 699 EUR	—	—	44 446 EUR	—	—	—	—	73 173 EUR